Stock NTRA NATERA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Natera, Inc.

Equities

NTRA

US6323071042

Market Closed - Nasdaq
Other stock markets
 01:30:00 22/06/2024 am IST 		5-day change 1st Jan Change
107.1 USD -0.08% Intraday chart for Natera, Inc. -2.80% +70.99%
17/06 Natera Adds New Feature to Prospera Heart Test to Improve Detection of Rejection in Transplant Patients MT
17/06 Natera, Inc. Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Natera Adds New Feature to Prospera Heart Test to Improve Detection of Rejection in Transplant Patients
Natera, Inc. Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients
U.S. FDA advisers back approval for Guardant's cancer test
Natera Insider Sold Shares Worth $3,137,567, According to a Recent SEC Filing
Top Premarket Gainers
Natera Q1 Loss Narrows, Revenue Rises; Full-Year Revenue Guidance Raised -- Shares Jump After Hours
Natera, Inc. Provides Earnings Guidance for the Year 2024
Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Natera, Inc. Announces a New Publication in JCO Precision Oncology Reporting on the Ability of its Personalised and Tumor-Informed Molecular Residual Disease Test, Signatera
Natera, Inc. Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer
Natera Insider Sold Shares Worth $534,331, According to a Recent SEC Filing
Natera Insider Sold Shares Worth $824,092, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTRA Stock
  4. News Natera, Inc.
  5. Other languages